MX2010010115A - Peptidos muy puenteados a partir de actinomadura namibiensis. - Google Patents
Peptidos muy puenteados a partir de actinomadura namibiensis.Info
- Publication number
- MX2010010115A MX2010010115A MX2010010115A MX2010010115A MX2010010115A MX 2010010115 A MX2010010115 A MX 2010010115A MX 2010010115 A MX2010010115 A MX 2010010115A MX 2010010115 A MX2010010115 A MX 2010010115A MX 2010010115 A MX2010010115 A MX 2010010115A
- Authority
- MX
- Mexico
- Prior art keywords
- labyrinthopeptin
- actinomadura namibiensis
- bridged peptides
- prepro
- pro
- Prior art date
Links
- 241001065356 Actinomadura namibiensis Species 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La invención se refiere a los denominados derivados de las Labirintopeptina de la fórmula (I) (ver fórmula I) en la que {A}, {B}, {C}, R1-R6, m y n son como se definen en la presente memoria, obtenibles a partir de la cepa del microorganismo Actinomadura namibiensis (DSM 6313), a su uso para el tratamiento de infecciones bacterianas, infecciones víricas y/o el dolor, a una composición farmacéutica que los comprende, a prepro-Labirintopeptina, pro-Labirintopeptina, y DNA que codifica la preproLabirintopeptina y la pro-Labirintopeptina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290324 | 2008-04-02 | ||
| PCT/EP2009/001982 WO2009121483A1 (en) | 2008-04-02 | 2009-03-18 | Highly bridged peptides from actinomadura namibiensis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010010115A true MX2010010115A (es) | 2010-09-30 |
Family
ID=39730602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010115A MX2010010115A (es) | 2008-04-02 | 2009-03-18 | Peptidos muy puenteados a partir de actinomadura namibiensis. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110144001A1 (es) |
| EP (1) | EP2271665B1 (es) |
| JP (1) | JP5653900B2 (es) |
| KR (1) | KR101612275B1 (es) |
| CN (1) | CN102046652B (es) |
| AR (1) | AR071125A1 (es) |
| AT (1) | ATE541856T1 (es) |
| AU (1) | AU2009231118B2 (es) |
| BR (1) | BRPI0910985A2 (es) |
| CA (1) | CA2720173A1 (es) |
| CL (1) | CL2009000791A1 (es) |
| IL (1) | IL208239A0 (es) |
| MX (1) | MX2010010115A (es) |
| MY (1) | MY159790A (es) |
| RU (1) | RU2498995C2 (es) |
| WO (1) | WO2009121483A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1908774A1 (en) * | 2006-10-06 | 2008-04-09 | sanofi-aventis | Antibacterial and antiviral peptides from Actinomadura namibiensis |
| AU2009223838B2 (en) | 2008-03-03 | 2012-07-26 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
| EP2274001A4 (en) | 2008-03-20 | 2012-08-01 | Univ Miami | VACCINATION WITH HEAT SHOCK PROTEIN GP96 AND APPLICATION METHOD THEREFOR |
| EP2607374A1 (en) * | 2011-12-21 | 2013-06-26 | Sanofi | Method for recombinant production of labyrinthopeptins and functional derivatives thereof |
| JP6195618B2 (ja) * | 2012-07-12 | 2017-09-13 | ナイコンス, エセエッレエレNaicons, Srl | 新規ランチペプチド |
| US20190046604A1 (en) | 2015-11-18 | 2019-02-14 | Helmholtz-Zentrum für Infektionsforschung GmbH | Labyrinthopeptins as anti-viral agents |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0700998T3 (da) * | 1994-09-12 | 2004-03-29 | Aventis Pharma Gmbh | Rekombinant mersacidin samt en fremgangsmåde til fremstilling deraf |
| US5942423A (en) | 1995-06-07 | 1999-08-24 | Massachusetts Institute Of Technology | Conversion of compactin to pravastatin by actinomadura |
| DE602004020657D1 (de) * | 2003-12-02 | 2009-05-28 | Sanol Arznei Schwarz Gmbh | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen |
| CN100516218C (zh) * | 2006-04-30 | 2009-07-22 | 中山大学 | 一种新的线纹芋螺毒素序列、制备方法及其应用 |
| EP1908774A1 (en) * | 2006-10-06 | 2008-04-09 | sanofi-aventis | Antibacterial and antiviral peptides from Actinomadura namibiensis |
| EP2607374A1 (en) * | 2011-12-21 | 2013-06-26 | Sanofi | Method for recombinant production of labyrinthopeptins and functional derivatives thereof |
-
2009
- 2009-03-18 CA CA2720173A patent/CA2720173A1/en not_active Abandoned
- 2009-03-18 MY MYPI2010004183A patent/MY159790A/en unknown
- 2009-03-18 AT AT09728150T patent/ATE541856T1/de active
- 2009-03-18 RU RU2010144778/10A patent/RU2498995C2/ru not_active IP Right Cessation
- 2009-03-18 CN CN200980120478.5A patent/CN102046652B/zh not_active Expired - Fee Related
- 2009-03-18 BR BRPI0910985A patent/BRPI0910985A2/pt not_active IP Right Cessation
- 2009-03-18 KR KR1020107022012A patent/KR101612275B1/ko not_active Expired - Fee Related
- 2009-03-18 EP EP09728150A patent/EP2271665B1/en not_active Not-in-force
- 2009-03-18 AU AU2009231118A patent/AU2009231118B2/en not_active Ceased
- 2009-03-18 JP JP2011502252A patent/JP5653900B2/ja not_active Expired - Fee Related
- 2009-03-18 MX MX2010010115A patent/MX2010010115A/es active IP Right Grant
- 2009-03-18 WO PCT/EP2009/001982 patent/WO2009121483A1/en not_active Ceased
- 2009-03-31 CL CL2009000791A patent/CL2009000791A1/es unknown
- 2009-03-31 AR ARP090101143A patent/AR071125A1/es unknown
-
2010
- 2010-09-19 IL IL208239A patent/IL208239A0/en not_active IP Right Cessation
- 2010-09-30 US US12/895,106 patent/US20110144001A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011516048A (ja) | 2011-05-26 |
| CA2720173A1 (en) | 2009-10-08 |
| RU2010144778A (ru) | 2012-05-10 |
| WO2009121483A1 (en) | 2009-10-08 |
| AR071125A1 (es) | 2010-05-26 |
| IL208239A0 (en) | 2010-12-30 |
| EP2271665A1 (en) | 2011-01-12 |
| EP2271665B1 (en) | 2012-01-18 |
| MY159790A (en) | 2017-01-31 |
| CL2009000791A1 (es) | 2009-10-09 |
| JP5653900B2 (ja) | 2015-01-14 |
| HK1155762A1 (en) | 2012-05-25 |
| ATE541856T1 (de) | 2012-02-15 |
| CN102046652A (zh) | 2011-05-04 |
| CN102046652B (zh) | 2014-11-05 |
| US20110144001A1 (en) | 2011-06-16 |
| AU2009231118B2 (en) | 2013-06-27 |
| KR101612275B1 (ko) | 2016-04-14 |
| KR20110014563A (ko) | 2011-02-11 |
| AU2009231118A1 (en) | 2009-10-08 |
| RU2498995C2 (ru) | 2013-11-20 |
| BRPI0910985A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021226436A8 (en) | Optimized nucleotide sequences encoding sars-cov-2 antigens | |
| AR110834A2 (es) | MOLÉCULA DE UNA VARIANTE AISLADA DE FENILALANINA AMONIACOLIASA DE ANABAENA VARIABILIS (AvPal) | |
| CA2747703C (en) | Compositions and methods for the treatment or the prevention of infections by e. coli | |
| MX2009008139A (es) | Derivdos de 2-5a y su uso como agentes anti-cancer, antivirales y anti-parasitos. | |
| NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
| UA110199C2 (xx) | Тверда дисперсія рифаксиміну | |
| CY1118029T1 (el) | Βακτηριοφαγος ή λυτικη πρωτεϊνη που προερχεται απο το βακτηριοφαγο που ειναι αποτελεσματικα για την αντιμετωπιση βιομεμβρανης απο staphylococcus aureus | |
| IN2012DN00869A (es) | ||
| MY158325A (en) | Multitype peptide compositions and methods for treatment or prevention of human papillpmavirus infection | |
| WO2010090860A3 (en) | Methods and compositions for treating bacterial infection | |
| IN2012DN01233A (es) | ||
| EA201100505A1 (ru) | Органические соединения для применения для лечения бактериальных инфекций | |
| MY159790A (en) | Highly bridged peptides from actinomadura namibiensis | |
| EP4327874A3 (en) | 3,6-disubstituted xanthylium salts | |
| MX2011012643A (es) | 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal. | |
| CY1114883T1 (el) | Καινοφανεις αντιβακτηριακοι παραγοντες για την αγωγη των κατα gram θετικων λοιμωξεων | |
| MX2010008555A (es) | Bacteria recombinante con sistema de secrecion de hemolisina de e-coli y expresion incrementada y/o secrecion de hiya. proceso de elaboracion y usos de la misma. | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| MX2014001599A (es) | 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas. | |
| WO2012006149A3 (en) | Analogs of c5a and methods of using same | |
| MX359084B (es) | Péptidos antimicrobianos. | |
| WO2012017434A3 (en) | Guanine nucleotide derivatives for treating bacterial infections | |
| WO2009116044A3 (en) | Guanine nucleotide derivatives for treating bacterial infections | |
| EP2344642B8 (en) | Novel bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus enterococcus | |
| NZ590276A (en) | Use of nifurtimox for treating giardiasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |